lirentelimab

Lirentelimab is a humanized, nonfucosylated IgG1 monoclonal antibody that targets sialic acid-binding immunoglobulin-like lectin 8 (Siglec-8), an inhibitory receptor expressed primarily on eosinophils and mast cells. By binding to Siglec-8, lirentelimab depletes eosinophils through antibody-dependent natural killer cell-mediated cytotoxicity and inhibits mast cell activation and degranulation. It has been investigated for the treatment of diseases characterized by elevated eosinophil or mast cell activity such as eosinophilic gastritis, duodenitis, chronic spontaneous urticaria, atopic dermatitis, indolent systemic mastocytosis, severe allergic conjunctivitis, and other related conditions. Lirentelimab was developed by Allakos with initial discovery at Johns Hopkins University School of Medicine. As of early 2024 it has no approved indications; clinical development was discontinued after Phase 2 trials in atopic dermatitis and chronic spontaneous urticaria failed to meet primary endpoints[1][3][6].

Brand names

AK002AK-002AK 002

Other names

antolimabrecombinant humanized non-fucosylated IgG1 anti-Siglec-8 monoclonal antibody